Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast Cancer (EndoTAG-1)

This study has been completed.
Information provided by (Responsible Party):
Jules Bordet Institute Identifier:
First received: September 20, 2011
Last updated: June 14, 2013
Last verified: February 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2012
  Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)